Artikel
Genes and molecular pathways involved in radioresistance of sporadic and NF2-associated vestibular schwannomas: a microarray and pathway analysis
Suche in Medline nach
Autoren
Veröffentlicht: | 9. Juni 2017 |
---|
Gliederung
Text
Objective: Vestibular schwannomas (VSs) are benign tumors of the eighth cranial nerve which occur either as sporadic unilateral tumors or bilateral as a hallmark of neurofibromatosis type 2 (NF2). Besides microsurgical resection or chemotherapy in case of NF2-associated VSs, more recently stereotactic radiosurgery (SRS) and fractionated stereotactic radiotherapy (FSRT) have gained acceptance as effective alternatives. However, there is a subset of radioresistant tumors that continue to grow after radiation treatment. Radioresistant behavior at the molecular level as well as the differences between irradiated sporadic and NF2-associated VSs are not well understood. The objective of this study was to provide insight into the radiobiology of sporadic and NF2-associated VSs through gene expression profiling and pathway analysis.
Methods: 49 non-irradiated and 7 irradiated recurrent VS tumors were fresh-frozen at the time of surgical resection and RNA isolation was performed for cDNA microarray analysis (HG-U219 Array Plate, Affymetrix®). We utilized canonical pathway analysis (Ingenuity Pathway Analysis) to investigate pathways involved in radioresistance.
Results: A total of 195 probe sets (128 probe sets were up- and 67 downregulated) showed significant difference based on the criteria of P value < 0.01 and absolute fold change ≥ 2. These genes were involved in deregulation of important pathways known to be involved in radioresistance (e.g. NF-κB Signaling, STAT3 signaling, p53 signaling, ect.) resulting in proliferation, hypoxia, angiogenesis and cell cycle interruption.
Conclusion: Irradiated sporadic and NF2-associated tumors share common modifications of pathways which contribute to radioresistance in tumors and could be a reason for acquired resistance to radiation. These pathways and their participating genes might function as candidate therapeutic targets for radiosensitizers in the future.